KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Deferred Taxes (2017 - 2019)

Amneal Pharmaceuticals has reported Deferred Taxes over the past 3 years, most recently at $33000.0 for Q4 2019.

  • Quarterly results put Deferred Taxes at $33000.0 for Q4 2019, up 110.06% from a year ago — trailing twelve months through Sep 2020 was $33000.0 (down 99.99% YoY), and the annual figure for FY2019 was $371.7 million, up 4038.09%.
  • Deferred Taxes for Q4 2019 was $33000.0 at Amneal Pharmaceuticals, down from $389.9 million in the prior quarter.
  • Over the last five years, Deferred Taxes for AMRX hit a ceiling of $389.9 million in Q3 2019 and a floor of -$14.5 million in Q2 2018.
  • Median Deferred Taxes over the past 3 years was -$420000.0 (2018), compared with a mean of $36.3 million.
  • Peak annual rise in Deferred Taxes hit 6528.56% in 2019, while the deepest fall reached 1830.47% in 2019.
  • Amneal Pharmaceuticals' Deferred Taxes stood at $1.3 million in 2017, then plummeted by 125.71% to -$328000.0 in 2018, then soared by 110.06% to $33000.0 in 2019.
  • The last three reported values for Deferred Taxes were $33000.0 (Q4 2019), $389.9 million (Q3 2019), and -$8.3 million (Q2 2019) per Business Quant data.